Title:
MEDICINAL COMPOSITION FOR PREVENTING OR TREATING SECONDARY HYPERPARATHYROIDISM UNDER MAINTENANCE DIALYSIS
Document Type and Number:
WIPO Patent Application WO/2019/124411
Kind Code:
A1
Abstract:
A medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis, said medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carmaboylamino}-5-chloro-4-methylbenzenesulfonic acid or a pharmaceutically acceptable salt thereof, or a solvate of the same which is to be administered by a predefined route in a predefined dosage. According to the present invention, it is possible to provide a prophylactic or therapeutic agent for secondary hyperparathyroidism under maintenance dialysis, said agent showing reduced side effects or no significant accumulation. This medicinal agent allows easy administration management and has a high safety compared with conventional products.
Inventors:
KATAOKA DAISUKE (JP)
KUYAMA KAZUO (JP)
ASANO KENJI (JP)
WAGATSUMA HIROTAKA (JP)
TSURUTA ATSUSHI (JP)
TAKANOHASHI TOSHIYUKI (JP)
KUYAMA KAZUO (JP)
ASANO KENJI (JP)
WAGATSUMA HIROTAKA (JP)
TSURUTA ATSUSHI (JP)
TAKANOHASHI TOSHIYUKI (JP)
Application Number:
PCT/JP2018/046679
Publication Date:
June 27, 2019
Filing Date:
December 19, 2018
Export Citation:
Assignee:
EA PHARMA CO LTD (JP)
International Classes:
A61K31/198; A61P5/18; C07C275/42
Domestic Patent References:
| WO2011108690A1 | 2011-09-09 | |||
| WO2011108690A1 | 2011-09-09 | |||
| WO2011014707A2 | 2011-02-03 |
Foreign References:
| JP2013063971A | 2013-04-11 | |||
| JP2013063971A | 2013-04-11 |
Other References:
NOBUO NAGANOTAKEHISA KAWATAMICHIHITO WADA: "Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA (registered trademark) tablet)", FOLIA PHARMACOLOGICA JAPONICA, vol. 132, 2008, pages 301 - 308
FUKAGAWA M ET AL.: "KRN1493 study group, Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients", NEPHROL DIAL TRANSPLANT, vol. 23, no. 1, 2008, pages 328 - 35
"Development History", vol. 1, April 2015, KYOWA HAKKO KIRIN, article "REGPARA (registered trademark) tablet, Medicine Interview Form"
GINCHERMAN Y ET AL.: "Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis", HEMODIAL INT., vol. 14, no. 1, 2010, pages 68 - 72
TOSHIYUKI DATE: "Dialysis Treatment Next IX", 2009, IGAKUTOSHO SHUPPAN, article "Toshiyuki DATE, Side effects of Cinacalcet and Countermeasures Thereof", pages: 123 - 32
"V. Items Relating to Treatment", vol. 8, ONO PHARMACEUTICAL CO., LTD., article "PARSABIV (registered trademark), Medicine Interview Form", pages: 47 - 50
KIDNEY INTERNATIONAL REPORTS, vol. 2, 2017, pages 634 - 644
CLINICAL NEPHROLOGY, vol. 88, no. 2, 2017, pages 68 - 78
FOLIA PHARMACOLOGICA JAPONICA, vol. 132, 2008, pages 301 - 308
NEPHROL DIAL TRANSPLANT, vol. 23, no. 1, 2008, pages 328 - 35
HEMODIAL INT., vol. 14, no. 1, 2010, pages 68 - 72
"Items Relating to Treatment", ONO PHARMACEUTICAL CO., LTD., article "PARSABIV (registered trademark) Medicine Interview Form", pages: 47 - 50
KIMURA T., EUR J PHARMACOL., vol. 407, no. 3, 3 November 2000 (2000-11-03), pages 327 - 32
LIU J, J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI., vol. 971, 15 November 2014 (2014-11-15), pages 35 - 42
See also references of EP 3730134A4
FUKAGAWA M ET AL.: "KRN1493 study group, Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients", NEPHROL DIAL TRANSPLANT, vol. 23, no. 1, 2008, pages 328 - 35
"Development History", vol. 1, April 2015, KYOWA HAKKO KIRIN, article "REGPARA (registered trademark) tablet, Medicine Interview Form"
GINCHERMAN Y ET AL.: "Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis", HEMODIAL INT., vol. 14, no. 1, 2010, pages 68 - 72
TOSHIYUKI DATE: "Dialysis Treatment Next IX", 2009, IGAKUTOSHO SHUPPAN, article "Toshiyuki DATE, Side effects of Cinacalcet and Countermeasures Thereof", pages: 123 - 32
"V. Items Relating to Treatment", vol. 8, ONO PHARMACEUTICAL CO., LTD., article "PARSABIV (registered trademark), Medicine Interview Form", pages: 47 - 50
KIDNEY INTERNATIONAL REPORTS, vol. 2, 2017, pages 634 - 644
CLINICAL NEPHROLOGY, vol. 88, no. 2, 2017, pages 68 - 78
FOLIA PHARMACOLOGICA JAPONICA, vol. 132, 2008, pages 301 - 308
NEPHROL DIAL TRANSPLANT, vol. 23, no. 1, 2008, pages 328 - 35
HEMODIAL INT., vol. 14, no. 1, 2010, pages 68 - 72
"Items Relating to Treatment", ONO PHARMACEUTICAL CO., LTD., article "PARSABIV (registered trademark) Medicine Interview Form", pages: 47 - 50
KIMURA T., EUR J PHARMACOL., vol. 407, no. 3, 3 November 2000 (2000-11-03), pages 327 - 32
LIU J, J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI., vol. 971, 15 November 2014 (2014-11-15), pages 35 - 42
See also references of EP 3730134A4
Attorney, Agent or Firm:
KOBAYASHI Hiroshi et al. (JP)
Download PDF:
Previous Patent: COSMETIC RAW MATERIAL, AND SKIN COSMETIC CONTAINING SAME
Next Patent: SULFONIC ACID ESTER COMPOUND AND USE OF SAME
Next Patent: SULFONIC ACID ESTER COMPOUND AND USE OF SAME